GlassScriptPhysician profile
Robert A Harris
NPI 1508047085
$8,314.73
in general payments reported to CMS, 2019-2025
28 companies · $2,183 in 2025
The $2,183 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $998 · 2023: $1,801 · 2024: $2,445 · 2025: $2,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,429.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,603.09 | 2021-2025 | |
| Pfizer INC. | $1,026.42 | 2021-2025 | |
| Lilly USA, LLC | $954.60 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $908.42 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $469.18 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $441.62 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.57 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $243.00 | 2021-2025 | Gardasil 9, Capvaxive, Verquvo |
| Otsuka America Pharmaceutical, INC. | $237.41 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $215.07 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $146.06 | 2021-2024 | Xarelto |
| Nestle Healthcare Nutrition INC. | $130.95 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $104.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.62 | 2023-2025 | |
| Medtronic, INC. | $56.85 | 2024 | Minimed 780g |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $51.79 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $48.93 | 2021 | |
| Bausch Health US, LLC | $41.96 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.62 | 2021 | |
| Abbott Laboratories | $28.57 | 2025 | Freestyle Libre 3 |
| Allergan, INC. | $26.67 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.64 | 2022 | |
| Heartflow, INC. | $24.55 | 2024 | |
| Becton, Dickinson and Company | $21.33 | 2025 | Bd Onclarity |
| Xeris Pharmaceuticals, INC. | $20.27 | 2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $17.70 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $15.78 | 2023 | Nexletol |
| Idorsia Pharmaceuticals US INC | $15.26 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.